PACE: prognostic and predictive biomarkers in ER+/HER2- advanced breast cancer

Guilherme Nader-Marta, MD, Dana-Farber Cancer Center, Boston, MA, gives an overview of two key studies from the PACE trial (NCT03147287), which explored biomarkers in ER+/HER2- metastatic breast cancer. The first examines thymidine kinase activity (TKa) dynamics and their prognostic value, showing that early TKa changes predict distinct outcomes. The second evaluates DNADX, a machine learning approach using ctDNA data, which identified five tumor subtypes with implications for prognosis and treatment benefit. This interview took place at the 2024 San Antonio Breast Cancer Symposium (SABCS) congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.